Pyrimido\x9b5,4!-dipyrimidines, pharmaceuticals containing them, their use
申请人:Dr. Karl Thomae GmbH
公开号:US05821240A1
公开(公告)日:1998-10-13
Pyrimido\x9b5,4-d!pyrimidines of the general formula ##STR1## which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-\x9b(3-Chloro-4-fluorophenyl)amino!-6-\x9b1-methyl-4-piperidinylamino!pyrimido\x9b 5,4-d!pyrimidine, and 4-\x9b(3-Chloro-4-fluorophenyl)amino!-6-\x9btrans-4-dimethyl-aminocycohexylamino! pyrimido\x9b5,4-d!pyrimidine.
and MN19, characterized by rings with different size, have been prepared and evaluated for their nootropic activity in the mouse passive-avoidance test. It was found that the optimal ringsize for the analogs of DM235, showing endocyclic both amidic groups, is 6 or 7 atoms. For the compounds structurally related to MN19, carrying an exocyclic amide group, the piperidine ring is the moiety which gives